DOJ policy shakes up healthcare fraud enforcement landscape

The gist

The DOJ’s new enforcement playbook is exposing a sharp divide: individuals get prison, while corporations write checks and walk away.

What to know

Justice Gap: Individuals vs. Corporations

While doctors face decades behind bars for fraud, corporate giants like CVS avoid criminal charges by paying massive settlements—highlighting a persistent double standard in healthcare enforcement.

By mid-2026, high-profile healthcare fraud cases vividly illustrated the stark contrast in enforcement outcomes between individual perpetrators and large corporations. Dr. Sanjeev Kumar received a 20-year prison sentence for orchestrating a $41 million medical billing fraud involving the reuse of single-use devices in over 15,000 hysteroscopies, exposing thousands of women to unsafe procedures. However, while Kumar faced severe criminal penalties, corporate giant CVS Health resolved two major fraud allegations—improper insulin billing and false prescription claims by its Omnicare subsidiary—with nearly $500 million in civil settlements, yet no executives faced criminal charges or prison time. This dichotomy underscores a persistent enforcement pattern where individuals bear harsh punitive consequences, whereas corporations often settle financially to move past allegations without admitting wrongdoing.

CVS Health’s settlements in 2026 highlight the immense scale and complexity of corporate healthcare fraud schemes. The company agreed to pay $36.5 million for over-dispensing insulin and a staggering $440 million for Omnicare’s submission of more than 3.3 million false prescription claims to Medicare, Medicaid, and TRICARE. These cases reveal how fraudulent billing practices can permeate multiple facets of healthcare delivery, involving both direct patient care products and ancillary services, and demonstrate the government’s willingness to pursue substantial financial penalties to deter such widespread abuse.

Sources
Business Blunders

Fraud Tactics Get Sophisticated

Telemedicine scams, device misuse, and high-tech billing tricks are pushing regulators to deploy advanced analytics and rapid-response teams to catch increasingly complex healthcare fraud.

Healthcare fraud schemes have evolved into a complex web spanning telemedicine, medical devices, and individual practitioners, with recent cases revealing fraud amounts exceeding $136 million. This broad spectrum underscores the multifaceted nature of abuse, from telehealth company CEOs to medical device manufacturers and physicians, all caught in the enforcement crosshairs. Such diversity in defendants highlights the pervasive challenges regulators face in safeguarding the integrity of healthcare billing.

Government detection efforts have intensified, exemplified by CMS's Medicaid Fraud War Room, which swiftly identified over $203 million in potentially improper Medicaid payments within a condensed timeframe. This proactive stance demonstrates an enhanced capacity to pinpoint high-risk providers and disrupt fraudulent schemes before they escalate, signaling a new era of vigilant oversight in healthcare compliance.

Sources

DOJ’s New Playbook Unveiled

A single, sweeping policy now governs corporate healthcare crime, rewarding companies that self-report and cooperate with sharply reduced penalties and even prosecution declinations.

The Department of Justice fundamentally reshaped corporate criminal enforcement with its inaugural departmentwide Corporate Enforcement and Voluntary Self-Disclosure Policy, unveiled on March 10, 2023. This landmark policy replaced a fragmented array of division-specific guidelines, establishing a unified framework applicable to all corporate criminal matters except antitrust violations. By early 2026, the policy's real-world impact was underscored when the DOJ’s National Fraud Enforcement Division declined prosecution against Campus Eye Management Holdings on July 29, marking the first healthcare-sector resolution under this new regime and signaling a pivotal shift in enforcement strategy.

At the heart of the policy lies a clear incentive structure: companies that voluntarily self-disclose misconduct, fully cooperate, promptly remediate issues, and avoid aggravating circumstances may receive complete declination of prosecution, though they remain liable for disgorgement, forfeiture, and victim restitution. This nuanced approach balances accountability with encouragement for transparency, as seen in Part I of the policy, which sets these stringent yet attainable conditions for full declination. The policy’s definition of voluntary self-disclosure is particularly exacting, requiring good-faith reporting before DOJ awareness, absence of prior legal disclosure obligations, and timely notification—typically within 120 days even when whistleblower complaints have surfaced internally and to the government, reflecting a sophisticated accommodation for complex corporate realities.

The policy’s tiered prosecutorial framework further refines enforcement outcomes by calibrating consequences to the degree of corporate cooperation and disclosure. Part I offers declinations for full compliance, while Part II addresses scenarios of partial compliance or presence of aggravating factors through nonprosecution agreements with reduced fines. Part III retains full prosecutorial discretion for cases lacking sufficient cooperation or involving serious misconduct, capping fine reductions at 50% and allowing for monitorships and varied resolution lengths. This graduated system underscores the DOJ’s strategic pivot towards incentivizing self-policing and remediation, while preserving robust tools to address recalcitrant or egregious offenders.

Sources

Campus Eye: A Test Case

The DOJ’s first declination under its new policy sent a clear message: companies that self-disclose and remediate can avoid prosecution, but executives behind the fraud still face personal charges.

The DOJ’s July 29, 2026 declination of Campus Eye Management Holdings LLC marked a watershed moment as the first application of the March 2026 Corporate Enforcement Policy (CEP) in the healthcare sector. This decision not only closed the investigation into Campus Eye but also underscored the DOJ’s evolving enforcement approach that balances corporate accountability with individual culpability, as evidenced by simultaneous charges against the company’s founder and former CEO, E. Bruce DiDonato. This dual-track enforcement signals the DOJ’s intent to hold individuals personally responsible while incentivizing companies to enhance compliance.

Campus Eye’s case vividly illustrates the CEP’s emphasis on proactive corporate behavior as a pathway to mitigating enforcement risk. By voluntarily self-disclosing misconduct, fully cooperating with investigators, promptly remediating identified issues, and committing to ongoing assistance, Campus Eye met the stringent CEP criteria that led to the declination. This outcome sends a clear message to healthcare entities that transparency and swift corrective action can substantially influence DOJ’s enforcement calculus.

Financial resolution under the CEP also demonstrated DOJ’s pragmatic flexibility, as it accepted a $1 million disgorgement payment from Campus Eye after an inability-to-pay analysis, rather than demanding the full $3.7 million in alleged fraudulent payments. This approach highlights the DOJ’s willingness to tailor remedies to preserve the viability of healthcare providers while still protecting federally funded programs from fraud, particularly in cases involving medically unnecessary testing and disguised kickbacks, which were central to the Campus Eye allegations.

Sources

Medicare Advantage: Risk Score Manipulation

Complete Health Partners’ $14.1 million settlement reveals how companies exploited risk adjustment formulas—pressuring clinicians to inflate diagnoses and maximize Medicare payouts.

In a landmark whistleblower-driven case, Complete Health Partners Holdings agreed in August 2026 to a $14.1 million settlement after the DOJ exposed a scheme from 2020 to 2023 where the company pressured clinicians to inflate Medicare Advantage risk scores by adding unsubstantiated diagnoses such as major depressive disorder and substance dependence. This manipulation was fueled by the company's risk-sharing contracts with Medicare Advantage plans, which financially rewarded overstating patient conditions, ultimately resulting in millions of dollars in improper payments from CMS. The case highlights the DOJ’s intensified crackdown on fraud schemes that exploit the financial incentives embedded in Medicare Advantage payment structures.

Sources

Home Health Fraud Under Siege

Federal strike forces and CMS moratoria are targeting rampant home health scams, blocking fraudulent agencies and prosecuting thousands in a bid to protect billions in taxpayer funds.

By August 2026, the DOJ's Health Care Strike Force intensified its crackdown on home health care fraud, charging 19 defendants in a $4 million Medicaid and Medicare scheme involving egregious false billing practices such as a home health aide allegedly logging over 1,100 hours in a single day across multiple clients. This case exemplifies the broader enforcement landscape, where the Strike Force has prosecuted over 6,200 defendants responsible for more than $45 billion in fraudulent claims, underscoring the scale and critical importance of these efforts to protect federal health care programs.

In direct response to the persistent surge in home health care fraud, CMS implemented six-month moratoria on new enrollments for home health agencies and hospices, aiming to stem the flow of illicit providers into the system. This preventative measure, coupled with CMS’s active collaboration with law enforcement agencies, reflects a strategic shift toward not only prosecuting offenders but also proactively identifying and blocking fraudulent operations before they can inflict further damage on Medicaid and Medicare programs.

Sources
Home Health Care News

Get the stories behind the trends

Deep-dive reporting and the weekly brief, in your inbox.